Does Killip class III predict mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention?
Killip class III remains a strong independent predictor of short- and long-term mortality in STEMI patients even in the era of primary PCI.
Killip III remains strongly and independently predictive of 30-day and 1-yr mortality in ST-segment elevation myocardial infarction patients even undergoing primary percutaneous coronary intervention.
Tsai et al. (Tue,) studied this question.